Magnesium Toxicity and Management in Obstetrics

Quick Answer

One-liner: Magnesium toxicity in obstetrics is a potentially life-threatening iatrogenic complication of therapeutic magnesium sulfate administration, characterized by progressive neuromuscular and cardiovascular depression that is reversed by calcium administration and supportive care.

Magnesium sulfate (MgSO4) is the standard of care for eclampsia prevention and treatment, as well as fetal neuroprotection in preterm delivery. However, the narrow therapeutic window (2.0-3.5 mmol/L for eclampsia prophylaxis) means toxicity is common (5-10% of patients) and potentially fatal if unrecognized [1]. The Magpie Trial established the 58% reduction in eclampsia with MgSO4, but highlighted the importance of monitoring [2].

Key Clinical Features by Serum Level:

• 3.5-5 mmol/L: Nausea, flushing, warmth, loss of patellar reflexes (earliest clinical sign)
• 5-6 mmol/L: Muscle weakness, hypotension, ECG changes (prolonged PR, QRS)
• 6-7 mmol/L: Respiratory depression, paralysis, profound hypotension

• 10 mmol/L: Cardiac arrest, complete heart block

Emergency Management:

1. STOP magnesium infusion immediately
2. Calcium gluconate 10-20 mL of 10% IV over 10 minutes (antagonizes Mg effects)
3. Airway management - bag-mask ventilation or intubation if apnoeic
4. Supportive care - IV fluids, monitoring, prepare for delivery if fetus compromised
5. Dialysis - for severe toxicity with renal failure (haemodialysis removes Mg effectively)

ICU Mortality: <1% with prompt recognition and treatment

Must-Know Facts:

• Loss of patellar reflexes is the earliest clinical sign of toxicity (occurs at 3.5-5 mmol/L)
• Calcium gluconate is the antidote - does not reverse Mg levels but antagonizes effects
• Renal impairment (common in pre-eclampsia) is the major risk factor for accumulation
• Fetal effects are significant - floppy baby syndrome, hyporeflexia, respiratory depression
• Therapeutic drug monitoring is essential - check Mg levels every 4-6 hours if renal impairment

---

CICM Exam Focus

What Examiners Expect

Second Part Written (SAQ):

Common SAQ stems:

• "A 32yo primigravida at 34 weeks gestation is receiving magnesium sulfate for severe pre-eclampsia. She becomes drowsy and her respiratory rate drops to 8/min. Outline your assessment and management."
• "Discuss the pharmacology of magnesium sulfate relevant to its use in obstetrics, including mechanism of action, dosing, monitoring, and toxicity management."
• "A woman with eclampsia and AKI requires ongoing magnesium therapy. Outline your approach to dosing and monitoring in the context of renal impairment."

Expected depth:

• Precise magnesium dosing (4g loading, 1g/hr maintenance)
• Toxicity thresholds by serum level with clinical correlation
• SOMANZ/RCOG/WHO guideline recommendations
• Risk factor identification (renal impairment, concurrent CCB)
• Antidote administration (calcium gluconate dose, mechanism)
• Fetal/neonatal considerations

Second Part Hot Case:

Typical presentations:

• Postpartum day 1, drowsy, hyporeflexic patient on magnesium infusion
• Pre-eclampsia patient with oliguria and progressive weakness
• Eclampsia patient post-seizure with respiratory depression

Examiners assess:

• Systematic A-E examination approach with obstetric focus
• Recognition of magnesium toxicity vs disease progression
• Differentiation from other causes of respiratory depression
• Appropriate escalation and team communication
• Fetal considerations if antepartum
• Family communication regarding prognosis

Second Part Viva:

Expected discussion areas:

• Magnesium physiology (NMDA antagonism, calcium channel blockade, NMJ effects)
• Pharmacokinetics in pregnancy vs renal impairment
• Monitoring protocols (reflexes, urine output, respiratory rate, serum levels)
• Magpie trial evidence and NNT for eclampsia prevention
• Fetal neuroprotection indications (BEAM trial, preterm delivery)
• Calcium gluconate pharmacology and dosing
• Dialysis considerations in severe toxicity

Common Mistakes

• Attributing drowsiness/respiratory depression to pre-eclampsia progression rather than Mg toxicity
• Failure to check reflexes and respiratory rate regularly during infusion
• Not reducing dose in renal impairment
• Delayed calcium gluconate administration
• Forgetting fetal/neonatal implications of magnesium toxicity
• Not recognizing concurrent CCB use as a potentiating factor

---

Key Points

Key Points: The 10 things you MUST know for CICM exams:

1. Therapeutic window: 2.0-3.5 mmol/L for eclampsia prophylaxis (narrow margin)

2. Loss of reflexes FIRST: Patellar reflexes lost at 3.5-5 mmol/L - the key clinical monitoring parameter

3. Respiratory depression is LATE: Occurs at 5-6 mmol/L - don't wait for this to recognize toxicity

4. Calcium gluconate is the ANTIDOTE: 10-20 mL of 10% IV over 10 minutes - antagonizes Mg effects

5. Renal impairment = major risk: Pre-eclampsia often causes AKI; reduce dose and monitor levels

6. Four monitoring parameters: Reflexes, respiratory rate, urine output, serum Mg level

7. Standard dosing: 4g loading over 20 min, then 1g/hour maintenance (SOMANZ 2023)

8. Magpie Trial: 58% reduction in eclampsia (NNT 63), established MgSO4 as standard of care

9. Fetal effects are real: Floppy baby, hyporeflexia, respiratory depression - especially if delivery within 2 hours of loading dose

10. Dialysis removes magnesium: Haemodialysis is effective for severe toxicity with renal failure

Memory Aid

Mnemonic "REFLEX" for Monitoring:

• Reflexes (patellar - must be present)
• Elimination (urine output >25 mL/hr)
• Frequency of breathing (RR >12/min)
• Level of serum Mg (check 4-6 hourly if risk factors)
• ECG (prolonged PR, QRS if toxic)
• X-tra risk factors (renal impairment, CCB use)

---

Definition & Epidemiology

Definition

Magnesium toxicity (hypermagnesemia) in obstetrics is defined as serum magnesium levels exceeding the therapeutic range (>3.5 mmol/L for eclampsia prophylaxis or >4.0 mmol/L absolute toxicity threshold), resulting in progressive neuromuscular, cardiovascular, and respiratory depression [3].

Clinical vs Biochemical Toxicity:

• Biochemical toxicity: Serum Mg >3.5 mmol/L
• Clinical toxicity: Presence of symptoms/signs (loss of reflexes, respiratory depression, hypotension)
• Severe toxicity: Serum Mg >5 mmol/L or respiratory compromise requiring intervention

Therapeutic Uses in Obstetrics

Epidemiology

Incidence of Toxicity:

• Symptomatic hypermagnesemia: 5-10% of patients receiving therapeutic MgSO4 [4]
• Severe toxicity (Mg >5 mmol/L): 1-2% of treated patients [5]
• Respiratory depression requiring intervention: 0.5-1% [6]
• Maternal mortality from Mg toxicity: <0.01% with appropriate monitoring [7]

Australian/NZ Specific Data:

• Pre-eclampsia/eclampsia accounts for 10-15% of obstetric ICU admissions [8]
• Magnesium-related adverse events reported in 8% of treated patients (ANZICS APD data)
• Higher rates of severe pre-eclampsia in Aboriginal/Torres Strait Islander women (OR 1.8) [9]
• Remote areas have delayed access to monitoring and treatment adjustment

Risk Factors for Toxicity:

Indigenous Health Considerations:

• Aboriginal and Torres Strait Islander women: 2-3× higher maternal mortality rates [10]
• Higher prevalence of chronic kidney disease (CKD) in Indigenous populations - increased toxicity risk
• Later presentation with more severe pre-eclampsia requiring higher Mg doses
• Remote communities: Delayed access to specialist monitoring and dialysis
• Māori women: 2× higher severe maternal morbidity rates (NZ data) [11]
• Cultural liaison and interpreter services essential for informed consent and monitoring education

---

Applied Basic Sciences

Magnesium Physiology

Normal Magnesium Homeostasis:

• Total body Mg: 25g (1000 mmol) in adult
• Distribution: 60% bone, 39% intracellular, 1% extracellular (only this is measured)
• Normal serum Mg: 0.70-1.05 mmol/L (1.7-2.5 mg/dL)
• Ionized (active) fraction: 55-60% of total
• Daily requirement: 8-12 mmol (200-300 mg)

Cellular Functions of Magnesium:

1. Enzyme Cofactor: Required for >300 enzymatic reactions including:

   • Na-K-ATPase (membrane potential maintenance)
   • All ATP-utilizing reactions (kinases, ATPases)
   • DNA/RNA polymerases
   • Protein synthesis machinery

2. Membrane Stabilization:

   • Modulates calcium and potassium channel activity
   • Stabilizes cardiac myocyte membranes (antiarrhythmic)
   • Reduces neuromuscular excitability

3. NMDA Receptor Antagonism:

   • Non-competitive antagonist at NMDA glutamate receptors
   • Reduces excitatory neurotransmission
   • Mechanism of anticonvulsant effect in eclampsia [12]
   • Provides neuroprotection in ischemia/hypoxia

4. Calcium Channel Blockade:

   • Blocks L-type voltage-gated calcium channels
   • Reduces calcium entry into smooth muscle and cardiomyocytes
   • Causes vasodilation (contributes to hypotension in toxicity)
   • Synergistic with CCBs - major drug interaction

Mechanism of Anticonvulsant Effect

Why Magnesium Prevents Eclamptic Seizures:

Cerebral Vasodilation:
Mg → Ca channel blockade → Smooth muscle relaxation → ↑ CBF → ↓ Cerebral ischaemia

NMDA Receptor Blockade:
Mg → Blocks NMDA receptor → ↓ Glutamate excitotoxicity → ↓ Seizure threshold

Blood-Brain Barrier:
Mg → Stabilizes BBB → ↓ Cerebral oedema → ↓ Seizure risk

Neuronal Membrane:
Mg → ↓ Neuronal excitability → ↑ Seizure threshold

Evidence Base [13]:

• Magpie Trial: 58% reduction in eclampsia vs placebo (RR 0.42, 95% CI 0.29-0.60)
• Superior to phenytoin: Collaborative Eclampsia Trial (PMID: 7584858)
• Superior to diazepam: 52% reduction vs diazepam (PMID: 7584858)

Neuromuscular Junction Effects

Mechanism of Neuromuscular Blockade:

Clinical Progression [14]:

1. Mild weakness: Difficulty with fine motor tasks
2. Proximal weakness: Difficulty rising from chair, raising arms
3. Respiratory muscle weakness: Shallow breathing, ↓ vital capacity
4. Diaphragmatic paralysis: Respiratory failure, apnoea
5. Complete paralysis: Flaccid quadriplegia

Potentiation of Neuromuscular Blocking Agents:

• Magnesium potentiates both depolarizing and non-depolarizing NMBAs
• Reduce NMBA doses by 25-50% in patients on magnesium [15]
• Prolonged paralysis post-general anaesthesia if Mg toxic
• Reversal agents (neostigmine) may be less effective

Cardiovascular Effects

Mechanism of Cardiovascular Depression:

1. Vasodilation:

   • L-type Ca channel blockade in vascular smooth muscle
   • ↓ Systemic vascular resistance
   • Dose-dependent hypotension
   • Flushing and warmth (therapeutic levels)

2. Negative Inotropy:

   • ↓ Calcium entry into cardiomyocytes
   • ↓ Myocardial contractility
   • Exacerbated by concurrent β-blockers

3. Conduction System Depression:

   • ↓ SA node automaticity
   • ↓ AV node conduction (prolonged PR interval)
   • Widened QRS (severe toxicity)
   • Complete heart block (extreme toxicity)

ECG Changes with Magnesium Levels [16]:

Pharmacokinetics in Pregnancy

Clinical Implications:

• Higher loading doses may be needed in pregnancy (↑ Vd)
• Maintenance doses similar or higher due to ↑ renal clearance
• BUT: Pre-eclampsia causes AKI → Reduced clearance → Accumulation risk
• Fetal levels equilibrate with maternal within 1-2 hours of loading dose

---

Clinical Features of Toxicity

Progressive Toxicity by Serum Level

Detailed Clinical Manifestations

Neurological:

• Early: Drowsiness, lethargy, confusion
• Progressive: Obtundation, areflexia
• Severe: Coma (differentiate from PRES/eclampsia encephalopathy)

Neuromuscular:

• Loss of deep tendon reflexes (patellar first, then upper limb)
• Proximal muscle weakness
• Respiratory muscle weakness (diaphragm, intercostals)
• Complete flaccid paralysis

Cardiovascular:

• Flushing, warmth (vasodilation)
• Hypotension (dose-dependent)
• Bradycardia
• Conduction abnormalities (heart block)
• Cardiac arrest (asystole or PEA)

Respiratory:

• Reduced respiratory rate (<12/min is concerning)
• Shallow breathing
• Respiratory failure and apnoea
• Requires mechanical ventilation

Gastrointestinal:

• Nausea and vomiting
• Constipation (smooth muscle relaxation)
• Paralytic ileus (severe toxicity)

Differentiation from Pre-eclampsia Progression

---

Risk Factors for Toxicity

Renal Impairment

Pre-eclampsia and AKI:

• AKI occurs in 5-10% of severe pre-eclampsia cases [17]
• Mechanisms: Renal vasoconstriction, endotheliosis, ATN
• Creatinine may underestimate degree of AKI in pregnancy (low baseline)
• Oliguria common (reduced elimination)

Dose Adjustment in Renal Impairment [18]:

Incorrect Dosing Errors

Common Dosing Errors:

1. Calculation errors: Confusion between grams and mmol (1g MgSO4·7H2O = 4 mmol Mg)
2. Concentration errors: Wrong dilution leading to overdose
3. Pump programming errors: Rate errors (mg/hr vs mL/hr)
4. Failure to adjust for renal function: Standard dose in AKI
5. Loading dose errors: Giving loading dose too rapidly

Safe Practice Recommendations:

• Standardized MgSO4 protocols with pre-printed orders
• Double-checking of infusion calculations
• Use of standardized concentrations (e.g., 8g in 100mL = 80 mg/mL)
• Electronic infusion pump with programmed limits
• Regular education and competency assessment

Concurrent Calcium Channel Blockers

Drug Interaction:

• Nifedipine (commonly used for BP control in pre-eclampsia)
• Both block L-type Ca channels → Synergistic effects
• Profound hypotension, neuromuscular weakness, cardiac depression
• Case reports of maternal collapse with concurrent use [19]

Recommendations:

• Avoid concurrent IV nifedipine and magnesium if possible
• If nifedipine necessary, use oral route and monitor closely
• Labetalol may be preferred first-line antihypertensive
• Document interaction risk in medication chart
• Close monitoring of BP, reflexes, respiratory rate

Other Risk Factors

• Concurrent sedatives: Opioids, benzodiazepines potentiate respiratory depression
• General anaesthesia: Magnesium potentiates neuromuscular blockers
• Dehydration: Concentrates magnesium, reduces clearance
• Hypocalcaemia: Potentiates magnesium effects on NMJ
• Myasthenia gravis: Absolute contraindication to MgSO4

---

ICU Management of Magnesium Toxicity

Initial Resuscitation (First 10 Minutes)

1. STOP MAGNESIUM INFUSION IMMEDIATELY
2. CALL FOR HELP - ICU team, obstetrics, anaesthetics, paediatrics (if antepartum)
3. HIGH-FLOW OXYGEN (15 L/min via non-rebreather)
4. ASSESS AIRWAY - Prepare for intubation if respiratory failure
5. IV ACCESS x2 (if not already in place)
6. CALCIUM GLUCONATE 10% - 10-20 mL IV over 10 minutes
7. CHECK SERUM Mg LEVEL (urgent)
8. CONTINUOUS MONITORING - ECG, SpO2, BP
9. ASSESS FETAL STATUS (if antepartum) - CTG
10. DOCUMENT TIME AND ACTIONS

Calcium Gluconate as Antidote

Mechanism of Action:

• Calcium DOES NOT lower serum magnesium levels
• Antagonizes magnesium effects at cellular level:
  • Competes at Ca channels (restores function)
  • Restores neuromuscular transmission
  • Improves cardiac conduction
  • Reverses vasodilation

Dosing Protocol [20]:

Calcium Gluconate vs Calcium Chloride:

• Ca gluconate: 9 mg/mL elemental Ca (0.23 mmol/mL) - SAFER for peripheral IV
• Ca chloride: 27 mg/mL elemental Ca (0.68 mmol/mL) - More potent, requires central line
• Ca gluconate preferred in obstetrics (less tissue necrosis if extravasation)

Monitoring During Calcium Administration:

• Continuous ECG (watch for hypercalcaemia: shortened QT, arrhythmias)
• Blood pressure
• Deep tendon reflexes (return is sign of efficacy)
• Respiratory rate and effort
• Ionized calcium level

Airway Management

Indications for Intubation:

• Apnoea or severe hypoventilation (RR <8/min, SpO2 <90%)
• Inability to protect airway (GCS <8, absent gag reflex)
• Failure to respond to calcium gluconate
• Cardiac arrest
• Imminent delivery requiring airway control

RSI Considerations:

• Avoid suxamethonium if possible (prolonged by Mg, hyperkalaemia risk)
• Rocuronium: Reduce dose by 50% (Mg potentiates NMBBs)
• Sugammadex available for rocuronium reversal
• Propofol or ketamine for induction (avoid additional hypotension)
• Pre-oxygenation essential (pregnant patients desaturate rapidly)

Post-Intubation:

• Lung-protective ventilation (low Vt, moderate PEEP)
• Maintain SaO2 >94% (fetal oxygenation if antepartum)
• Sedation titration (avoid excessive agents)
• Ongoing calcium and supportive care

Supportive Care

Cardiovascular Support:

• IV fluid bolus (500-1000 mL crystalloid) for hypotension
• Vasopressor if fluid-refractory (noradrenaline first-line)
• Avoid excessive fluid (pre-eclampsia = intravascular depletion + interstitial overload)
• Target MAP ≥65 mmHg, higher if eclampsia/fetal compromise

Monitoring:

• Continuous ECG with defibrillator available
• Arterial line for continuous BP and ABG access
• Urinary catheter with hourly output monitoring
• Serial serum Mg levels (every 2-4 hours until normalized)
• Electrolytes (Ca, K, PO4) - correct abnormalities

Enhanced Elimination:

• Forced diuresis: Limited efficacy but maintain urine output >100 mL/hr if possible
• Loop diuretics: May enhance Mg excretion (frusemide 20-40 mg IV)
• NOT first-line for acute toxicity (slow effect)

Dialysis for Severe Toxicity

Indications for Dialysis:

• Serum Mg >7.5 mmol/L with cardiovascular instability
• Refractory toxicity despite calcium gluconate
• Concurrent acute kidney injury requiring RRT
• Cardiac arrest from hypermagnesemia

Dialysis Efficacy [21]:

• Haemodialysis removes 70-80% of magnesium (highly dialyzable)
• CRRT: Slower but continuous removal; suitable for haemodynamically unstable patients
• Peritoneal dialysis: Less effective but can be used in low-resource settings

Practical Considerations:

• Emergency vascular access (femoral dialysis catheter)
• Standard bicarbonate dialysate (no additional Mg)
• 4-hour HD session typically sufficient for isolated toxicity
• Post-dialysis Mg levels may rebound (intracellular Mg redistributes)
• Continue monitoring for 24-48 hours post-dialysis

---

Prevention of Toxicity

Monitoring Protocol

Four Essential Monitoring Parameters:

Additional Monitoring:

• Blood pressure: Q15 min initially, then Q1 hour
• Oxygen saturation: Continuous
• Level of consciousness: Q1-2 hours
• ECG: Continuous in high-risk patients
• Fetal CTG: Continuous if antepartum

SOMANZ Monitoring Recommendations [22]

Dose Adjustment Protocol

Standard Dosing (Normal Renal Function):

• Loading: 4g MgSO4 IV over 20 minutes
• Maintenance: 1g/hour IV infusion
• Duration: 24 hours post-delivery or post-last seizure

Adjusted Dosing (Renal Impairment):

Avoiding Drug Interactions

High-Risk Drug Combinations:

---

Fetal and Neonatal Considerations

Placental Transfer

Pharmacokinetics of Placental Transfer [23]:

• Magnesium crosses placenta rapidly by passive diffusion
• Fetal levels equilibrate with maternal within 1-2 hours of loading dose
• Fetal:maternal ratio approximately 0.9-1.0 at equilibrium
• Higher fetal levels if prolonged maternal treatment (>24-48 hours)
• Neonatal elimination slower than maternal (immature renal function)

Fetal Effects

Antepartum Considerations:

• Fetal heart rate: May show reduced variability (benign finding)
• Fetal movements: May be decreased (maternal perception and actual)
• Fetal neuroprotection: BENEFICIAL effect if preterm delivery anticipated

BEAM Trial Evidence (PMID: 18842817) [24]:

• MgSO4 given before preterm delivery (<32 weeks) reduces cerebral palsy
• NNT = 63 to prevent one case of cerebral palsy
• 4g IV loading dose for neuroprotection (no maintenance if delivery imminent)
• Mechanism: NMDA receptor blockade, reduced excitotoxicity

Neonatal Effects

Floppy Baby Syndrome [25]:

Clinical Features:

• Hypotonia: Generalized muscle weakness
• Hyporeflexia: Absent or diminished primitive reflexes
• Respiratory depression: May require resuscitation, CPAP, or ventilation
• Poor feeding: Weak suck, may need NG feeding
• Hypotension: Less common but can occur

Risk Factors for Neonatal Depression:

• Maternal Mg levels >3.5 mmol/L at delivery
• Delivery within 2 hours of loading dose
• Prolonged maternal treatment (>24-48 hours)
• Preterm infant (immature elimination)
• Concurrent maternal opioids or sedatives

Neonatal Management:

• Alert paediatric/neonatal team before delivery
• Prepare for resuscitation (bag-mask, intubation equipment)
• Calcium gluconate for neonate: 100-200 mg/kg IV (if severe)
• Supportive care: Warmth, respiratory support, feeding support
• Monitor for hypotension, respiratory depression
• Typically resolves within 24-72 hours as neonate clears magnesium

Neonatal Magnesium Levels:

Communication with Paediatric Team

Pre-Delivery Handover Should Include:

• Maternal indication for magnesium (eclampsia, pre-eclampsia, neuroprotection)
• Duration of magnesium therapy
• Last magnesium dose and current serum level
• Other maternal medications (opioids, sedatives)
• Gestational age and expected delivery mode
• Neonatal resuscitation plan

---

Australian/NZ Specific Considerations

SOMANZ Guidelines

Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) 2023 [22]:

Key Recommendations:

1. MgSO4 is first-line for eclampsia prophylaxis in severe pre-eclampsia
2. Standard dosing: 4g loading, 1g/hour maintenance
3. Duration: 24 hours post-delivery
4. Monitoring: Reflexes, RR, urine output, ± serum levels
5. Calcium gluconate must be available at bedside

Remote and Rural Considerations

RFDS and Retrieval Considerations:

• Limited access to serum Mg level monitoring in remote areas
• Reliance on clinical monitoring (reflexes, RR, urine output)
• Telemedicine consultation for dose adjustment
• Calcium gluconate must be available for transfers
• Consider shorter Mg infusion duration if retrieval to tertiary centre planned
• Inter-hospital transfer protocols for eclampsia/severe pre-eclampsia

Remote Community Management:

• Aboriginal Health Workers (AHWs) education on Mg monitoring
• Pre-prepared magnesium infusion kits with protocols
• Clear escalation pathways for toxicity
• Low threshold for retrieval if concerns

Indigenous Health Considerations

Barriers to Safe Magnesium Use:

• Later presentation with more severe disease
• Higher rates of renal impairment (pre-existing CKD)
• Language barriers affecting monitoring compliance
• Geographic isolation limiting access to specialist care
• Cultural factors in hospital care acceptance

Culturally Appropriate Care:

• Involvement of Aboriginal Liaison Officers (ALOs)
• Interpreter services for non-English speaking patients
• Family involvement in monitoring education
• Flexible visiting arrangements
• Recognition of cultural practices around birth
• Māori health considerations (NZ): Whānau involvement, Māori Health Workers

---

SAQ Practice Questions

SAQ 1: Magnesium Toxicity Recognition and Management

Time Allocation: 10 minutes Total Marks: 20

Stem: A 28-year-old primigravida at 36 weeks gestation with severe pre-eclampsia has been receiving magnesium sulfate (4g loading, 1g/hour maintenance) for 18 hours. She had an eclamptic seizure 6 hours ago with no recurrence. The midwife calls you urgently because the patient has become drowsy and her respiratory rate has dropped to 8/min.

Observations:

• HR: 72/min
• BP: 135/85 mmHg
• RR: 8/min
• SpO2: 92% on room air
• Temperature: 36.8°C
• GCS: 12 (E3V4M5)

Recent Investigations:

• Creatinine: 165 μmol/L (was 85 μmol/L on admission)
• Platelets: 125 × 10⁹/L
• Serum magnesium: Pending

---

Question 1.1 (8 marks)

List your immediate actions in the first 5 minutes and provide the rationale for each.

Question 1.2 (6 marks)

The serum magnesium returns at 5.8 mmol/L. Outline your ongoing management plan.

Question 1.3 (6 marks)

Discuss how you would prevent this complication in future patients receiving magnesium sulfate for pre-eclampsia.

---

Model Answer

Question 1.1 (8 marks)

Immediate Actions (First 5 Minutes):

---

Question 1.2 (6 marks)

Ongoing Management for Mg 5.8 mmol/L:

Airway and Breathing (2 marks):

• Bag-mask ventilation if apnoeic or RR <8/min unresponsive to calcium
• Intubation if: failure to improve, GCS deteriorates, airway unprotected
• RSI: Consider reduced NMBA dose (Mg potentiates paralysis)
• Target SpO2 >94% for maternal and fetal oxygenation

Circulation (1 mark):

• IV fluid bolus if hypotensive (500mL crystalloid)
• Vasopressor support if fluid-refractory
• Continuous ECG monitoring for arrhythmias

Drug Therapy (1 mark):

• Repeat calcium gluconate 10mL if inadequate response after 10 minutes
• Maximum 30-40mL total calcium gluconate
• Serial Mg levels every 2 hours until normalizing

Renal Considerations (1 mark):

• Creatinine risen from 85 to 165 μmol/L → AKI (contributor to toxicity)
• Forced diuresis if adequate volume status
• Consider dialysis if refractory toxicity or worsening AKI

Obstetric Considerations (1 mark):

• Urgent obstetric review for delivery planning
• Fetal distress may indicate need for emergency caesarean
• If delivery imminent, alert paediatric team (neonatal Mg effects)
• Continue care without Mg; alternative seizure prophylaxis if needed (labetalol for BP)

---

Question 1.3 (6 marks)

Prevention of Magnesium Toxicity:

Monitoring Protocol (2 marks):

• Check patellar reflexes every 1-2 hours (loss is earliest sign)
• Respiratory rate every 1 hour (>12/min target)
• Urine output every 1 hour (catheterized, target >25mL/hr)
• Serum Mg levels every 4-6 hours if renal impairment

Dose Adjustment for Renal Impairment (2 marks):

• This patient had rising creatinine (AKI) - should have triggered dose reduction
• Creatinine 165: Should have reduced to 0.5g/hour maintenance
• Oliguria should prompt dose reduction or cessation

Risk Factor Identification (1 mark):

• Pre-existing renal disease, concurrent CCBs, obesity
• Primigravida with severe pre-eclampsia = high risk for AKI

System Factors (1 mark):

• Standardized Mg protocols with dose adjustment tables
• Electronic prescribing with renal dose alerts
• Nursing education on monitoring parameters
• Calcium gluconate at bedside for all patients on Mg
• Clear escalation pathways if concerns

---

Examiner Comments:

• Candidates who immediately recognize Mg toxicity as cause (rather than pre-eclampsia progression) score well
• Must know calcium gluconate dose and mechanism
• Renal impairment as risk factor frequently missed
• Fetal considerations important for full marks

---

SAQ 2: Eclampsia with Renal Failure

Time Allocation: 10 minutes Total Marks: 20

Stem: A 34-year-old woman (G2P1) at 32 weeks gestation is transferred to your ICU from a rural hospital following two eclamptic seizures. She received magnesium sulfate loading dose (4g IV) prior to transfer but the infusion was stopped during the 3-hour retrieval due to concerns about her renal function.

On arrival to ICU:

• Postictal, GCS 11 (E3V3M5)
• HR: 105/min, BP: 175/110 mmHg
• RR: 22/min, SpO2: 96% on 6L O2
• Urine output: 10mL in last 3 hours (catheterized)

Investigations:

• Creatinine: 285 μmol/L (baseline unknown)
• Urea: 18 mmol/L
• Platelets: 68 × 10⁹/L
• AST: 320 U/L, ALT: 280 U/L
• LDH: 850 U/L
• Serum Mg: 1.2 mmol/L (3 hours post-loading dose)

---

Question 2.1 (8 marks)

This patient has ongoing eclampsia risk and requires magnesium therapy. Outline your approach to magnesium dosing and monitoring given her renal failure.

Question 2.2 (6 marks)

The patient has a third seizure 2 hours later despite magnesium therapy. Outline your management.

Question 2.3 (6 marks)

Discuss the indications for renal replacement therapy in this patient.

---

Model Answer

Question 2.1 (8 marks)

Magnesium Dosing in Renal Failure:

Initial Assessment (2 marks):

• Severe AKI (Cr 285, oliguria 10mL/3hr = <5mL/hr)
• HELLP syndrome present (low platelets, elevated LFT, elevated LDH)
• Serum Mg 1.2 mmol/L after 3 hours = subtherapeutic (need maintenance)
• High seizure risk - benefit of Mg outweighs toxicity risk if monitored

Dosing Strategy (3 marks):

• Do NOT repeat loading dose (3 hours since last, some Mg still present)
• Start reduced maintenance: 0.5g/hour (half standard dose)
• Rationale: Creatinine >250, oliguria = severely impaired clearance
• May consider even lower (0.25g/hour) given profound oliguria

Monitoring Protocol (3 marks):

• Serum Mg level: Every 2-4 hours initially (not standard 4-6h)
• Target: 2.0-3.0 mmol/L (lower end of therapeutic range)
• Patellar reflexes: Every 1 hour
• Respiratory rate: Every 1 hour
• Continuous ECG (arrhythmia risk in HELLP and Mg toxicity)
• Urine output: Hourly (already oliguria - additional monitoring)
• Have calcium gluconate at bedside

Additional Considerations:

• Document interaction between HELLP, AKI, and Mg therapy
• Multidisciplinary discussion: ICU, obstetrics, nephrology
• Early delivery planning (definitive treatment for HELLP/eclampsia)

---

Question 2.2 (6 marks)

Management of Breakthrough Seizure:

Immediate Actions (2 marks):

• Protect from injury (side rails, soft surroundings)
• Left lateral position (prevent aspiration, optimize uteroplacental flow)
• High-flow oxygen, suction available
• Time seizure duration

Anticonvulsant Therapy (2 marks):

• Additional MgSO4 2g IV over 5 minutes (standard recurrent seizure dose)
• Check current Mg level urgently
• If Mg already therapeutic (>2.5mmol/L) or toxic: Consider benzodiazepine
• Midazolam 2-5mg IV or diazepam 5-10mg IV as adjunct

Post-Ictal Assessment (2 marks):

• Reassess ABCDE, particularly airway protection
• Consider intubation if: Recurrent seizures, GCS <8, unable to protect airway
• CT head: Exclude intracranial hemorrhage, PRES
• Urgent obstetric review: Delivery timing
• Fetal assessment: CTG, may need emergency delivery if fetal distress

---

Question 2.3 (6 marks)

Indications for RRT in this Patient:

Absolute Indications (3 marks):

• Refractory hyperkalaemia (if develops) - not currently indicated
• Severe metabolic acidosis (pH <7.15) - check ABG
• Fluid overload unresponsive to diuretics (pulmonary oedema risk in pre-eclampsia)
• Uraemic complications (encephalopathy, pericarditis) - less likely acutely

Relative Indications in This Context (2 marks):

• Creatinine >265 μmol/L with oliguria (<100mL/6hr) = severe AKI, likely to need RRT
• Magnesium toxicity requiring enhanced elimination
• HELLP syndrome with worsening AKI (may need RRT as bridge to delivery)
• Ongoing need for Mg therapy but unable to clear drug

Practical Considerations (1 mark):

• CRRT preferred if haemodynamically unstable
• Haemodialysis more efficient for Mg removal if stable
• Dialysis catheter placement before delivery if possible
• Anticoagulation: Regional citrate or no anticoagulation (bleeding risk in HELLP)
• Coordinate with delivery timing

---

Examiner Comments:

• This SAQ tests integration of eclampsia, HELLP, AKI, and Mg pharmacology
• Candidates must demonstrate safe practice in high-risk scenarios
• Understanding of when to continue vs stop Mg therapy is key
• RRT indications should be specific, not generic lists

---

Viva Scenarios

Viva Scenario 1: Monitoring and Prevention

Stem: "A 30-year-old primigravida at 35 weeks with severe pre-eclampsia is admitted to your ICU for magnesium sulfate infusion and BP control. You are asked to discuss your approach to safe magnesium administration."

Duration: 12 minutes (2 min reading + 10 min discussion)

---

Opening Question: "How would you prescribe and monitor magnesium sulfate in this patient?"

Expected Answer:

Prescription:

• Loading dose: 4g MgSO4 IV over 20 minutes
• Maintenance: 1g/hour IV continuous infusion
• Duration: 24 hours post-delivery or post-last seizure
• Preparation: 40g MgSO4 in 500mL = 80 mg/mL (standardized)

Baseline Assessment:

• Check renal function (creatinine, urine output) before starting
• Document baseline reflexes and respiratory rate
• Review medications for interactions (CCBs, aminoglycosides)
• Ensure calcium gluconate 10% at bedside

Monitoring Protocol:

• Patellar reflexes: Every 1-2 hours (loss = first sign of toxicity)
• Respiratory rate: Every 1 hour (must be ≥12/min)
• Urine output: Hourly with catheter (target >25 mL/hr)
• Serum Mg levels: Every 4-6 hours if renal impairment; otherwise clinical monitoring
• BP: Q15min initially, then Q1h

---

Follow-up Question 1: "What are the mechanisms by which magnesium prevents eclamptic seizures?"

Expected Answer:

Four Main Mechanisms:

1. NMDA Receptor Antagonism:

   • Blocks glutamate binding at NMDA receptors
   • Reduces excitatory neurotransmission
   • Raises seizure threshold
   • Similar mechanism to ketamine (non-competitive antagonism)

2. Cerebral Vasodilation:

   • Blocks L-type calcium channels in cerebral vasculature
   • Increases cerebral blood flow
   • Reduces cerebral ischemia (which triggers seizures in eclampsia)

3. Blood-Brain Barrier Stabilization:

   • Reduces BBB permeability
   • Decreases cerebral edema (vasogenic)
   • May explain PRES improvement with Mg

4. Neuronal Membrane Stabilization:

   • Reduces neuronal excitability
   • Inhibits calcium-dependent neurotransmitter release

Evidence: Magpie Trial - 58% reduction in eclampsia (NNT 63) [2]

---

Follow-up Question 2: "The patient develops loss of patellar reflexes but is otherwise well. What is your approach?"

Expected Answer:

Immediate Actions:

• STOP magnesium infusion immediately
• Check respiratory rate - if >12/min and otherwise well, may be early toxicity
• Send urgent serum Mg level
• Document finding in notes

If Reflexes Only Absent (No Respiratory Depression):

• Hold infusion for 1-2 hours
• Recheck reflexes hourly
• When reflexes return, consider restarting at reduced rate (0.5g/hour)
• More frequent Mg level monitoring (q4h)

If Progression to Respiratory Depression:

• Give calcium gluconate 10mL of 10% IV over 10 minutes
• Supportive care as needed
• May not need to restart Mg if close to 24 hours or delivery imminent

Key Teaching Point:

• Loss of reflexes is the EARLIEST clinical sign
• It is the reason we check reflexes regularly
• Should prompt action BEFORE respiratory depression develops

---

Follow-up Question 3: "What are the considerations for the neonate if delivery occurs while the mother is on magnesium?"

Expected Answer:

Fetal/Neonatal Pharmacology:

• Mg crosses placenta rapidly (equilibrates in 1-2 hours)
• Fetal:maternal ratio approximately 0.9-1.0
• Neonatal elimination slower (immature renal function)

Neonatal Effects (Floppy Baby Syndrome):

• Hypotonia, hyporeflexia
• Respiratory depression (may need CPAP or ventilation)
• Poor feeding
• Usually resolves in 24-72 hours

Risk Factors for Severe Neonatal Effects:

• Maternal Mg >3.5 mmol/L at delivery
• Delivery within 2 hours of loading dose
• Prolonged maternal therapy (>24-48 hours)
• Preterm infant

Management:

• Alert paediatric team before delivery
• Prepare for resuscitation
• Calcium gluconate for neonate if severe (100-200 mg/kg)
• Supportive care (respiratory, feeding support)

Paradox: Mg also provides FETAL NEUROPROTECTION in preterm delivery (BEAM Trial) - beneficial when given for this indication

---

Examiner's Expected Level:

Pass:

• Safe prescribing and monitoring approach
• Understanding of at least two mechanisms of anticonvulsant effect
• Appropriate response to loss of reflexes
• Awareness of neonatal considerations

Fail:

• Unsafe dosing or inadequate monitoring
• No knowledge of mechanisms
• Delayed or inappropriate response to toxicity signs
• Unaware of fetal/neonatal effects

---

Viva Scenario 2: Toxicity Recognition and Management

Stem: "You are called urgently to the obstetric high-dependency unit. A 26-year-old woman at 38 weeks gestation receiving magnesium sulfate for eclampsia prophylaxis has become unresponsive with a respiratory rate of 6/min."

Duration: 12 minutes (2 min reading + 10 min discussion)

---

Opening Question: "What are your immediate concerns and actions?"

Expected Answer:

Immediate Concerns:

1. Magnesium toxicity - most likely given clinical picture
2. Airway compromise and respiratory failure
3. Cardiac toxicity (arrhythmias, arrest)
4. Fetal compromise (hypoxia from maternal respiratory failure)
5. Alternative diagnosis: Postictal state, PRES, intracranial hemorrhage

Immediate Actions (First 5 Minutes):

1. STOP magnesium infusion immediately
2. Call for help - ICU team, anaesthetics, obstetrics, paediatrics
3. Open airway - head tilt, chin lift; assess for obstruction
4. High-flow oxygen (15L NRB) and bag-mask ventilation if apnoeic
5. Calcium gluconate 10% 20mL IV over 2-5 minutes (emergency dose)
6. Check pulse and BP - assess for cardiac arrest
7. Prepare for intubation if no improvement
8. Check patellar reflexes (likely absent)
9. Urgent serum Mg level
10. CTG for fetal assessment (if possible, secondary priority)

---

Follow-up Question 1: "You give calcium gluconate and the patient improves slightly. Respiratory rate is now 10/min, reflexes remain absent. The magnesium level comes back at 6.5 mmol/L. What now?"

Expected Answer:

Ongoing Resuscitation:

• Continue supportive care; may need assisted ventilation
• Repeat calcium gluconate 10mL if response incomplete
• Monitor ECG for conduction abnormalities
• Check ionized calcium (don't overcorrect)

Assessment and Investigation:

• ABG: Assess ventilation (PaCO2 likely elevated), oxygenation
• Renal function: Check for AKI (cause of accumulation)
• Electrolytes: K, Ca, PO4
• ECG: PR prolongation, QRS widening

Enhanced Elimination:

• If renal function normal: Forced diuresis may help (limited efficacy)
• If AKI present: Consider haemodialysis (70-80% Mg removal)
• Dialysis indications: Refractory toxicity, cardiac instability, Mg >7.5 mmol/L

Obstetric Considerations:

• Urgent obstetric review
• If fetal distress: May need emergency caesarean
• If stable: Plan delivery when maternal status optimized
• No more magnesium - use alternative BP control (labetalol)

---

Follow-up Question 2: "How does calcium gluconate work as an antidote? Does it lower magnesium levels?"

Expected Answer:

Mechanism of Calcium as Antidote:

• Calcium does NOT reduce serum magnesium levels
• Works by antagonizing magnesium effects at cellular level

Specific Mechanisms:

1. Competition at Calcium Channels:

   • Both Mg and Ca compete for L-type Ca channels
   • Exogenous Ca displaces Mg, restores normal channel function
   • Restores cardiac conduction and vascular tone

2. Neuromuscular Junction:

   • Ca restores normal neurotransmitter release (presynaptic)
   • Restores postsynaptic receptor function
   • Reverses neuromuscular blockade

3. Cardiac Effects:

   • Restores normal automaticity and conduction
   • Improves contractility
   • Counters bradycardia and hypotension

Dosing:

• Calcium gluconate 10% = 9 mg/mL elemental calcium
• Standard dose: 10-20 mL (1-2g) IV over 10 minutes
• Emergency (cardiac arrest): 30 mL IV push
• May repeat every 5-10 minutes up to 30-40 mL total
• Ca chloride more potent but requires central access

Duration of Effect:

• Calcium has shorter half-life than magnesium
• Effect may wear off before Mg eliminated
• May need repeat doses or infusion

---

Follow-up Question 3: "After stabilization, the obstetric team wants to proceed with caesarean section. What are the anaesthetic considerations?"

Expected Answer:

Pre-operative Considerations:

• Airway assessment: Predict difficult airway in pre-eclampsia (edema)
• Consent: May need surrogate if patient lacks capacity
• Optimize: Ensure Mg level <4 mmol/L before GA if possible
• Blood products available (HELLP, bleeding risk)

General Anaesthesia Considerations:

• Neuromuscular Blocking Agents:

  • Magnesium potentiates both depolarizing and non-depolarizing agents
  • Reduce rocuronium dose by 50% (0.3 mg/kg instead of 0.6)
  • Avoid suxamethonium if possible (prolonged effect)
  • Sugammadex available for reversal

• Induction:

  • Propofol or ketamine (avoid additional hypotension)
  • RSI with cricoid pressure
  • Anticipate difficult airway

• Maintenance:

  • Volatile anaesthetic or TIVA
  • Minimal additional opioid (Mg + opioid = respiratory depression)
  • Monitor neuromuscular function (TOF)

Regional Anaesthesia Considerations:

• Spinal/epidural may be preferred if Mg level acceptable and platelets adequate
• Less drug interaction concerns
• Better for neonate (no GA drugs transferred)
• BUT: Platelet count must be checked (>80 × 10⁹/L for spinal)

Neonatal Preparation:

• Alert paediatric team to magnesium exposure
• Prepare for floppy, hypotonic neonate
• Calcium gluconate for neonate if severe depression

---

Examiner's Expected Level:

Pass:

• Immediate recognition and appropriate emergency response
• Correct calcium gluconate dosing
• Understanding that calcium antagonizes but doesn't lower Mg
• Awareness of anaesthetic implications

Fail:

• Delayed recognition or inappropriate response
• Not stopping magnesium infusion
• Incorrect antidote use
• Unsafe anaesthetic approach